Evolus (EOLS) Short term Debt (2017 - 2020)
Evolus (EOLS) posted Short term Debt of $74.4 million for Q4 2020, up 2.4% on a QoQ basis from $72.6 million in Q4 2017.
Evolus (EOLS) Short term Debt (2017 - 2020) Analysis & Trends
Evolus' Short term Debt history runs 2 years deep, the most recent figure standing at $74.4 million for Q4 2020.
- Quarterly Short term Debt changed N/A year-over-year to $74.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $74.4 million (changed N/A YoY) and the FY2020 annual result came in at $74.4 million, changed N/A from the prior year.
- Short term Debt was $74.4 million for Q4 2020 at Evolus, up from $72.6 million in the prior quarter.
- Across five years, Short term Debt topped out at $74.4 million in Q4 2020 and bottomed at $72.6 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 74.38 Mn |
| Dec 31, 2017 | 72.64 Mn |